SCLP vs. PRTC, OXB, HZD, FARN, VRP, ARIX, BVXP, CIR, 4BB, and AVCT
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Circassia Group (CIR), 4basebio (4BB), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.
Scancell vs. Its Competitors
Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
Scancell has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
In the previous week, PureTech Health had 2 more articles in the media than Scancell. MarketBeat recorded 3 mentions for PureTech Health and 1 mentions for Scancell. PureTech Health's average media sentiment score of 1.84 beat Scancell's score of 0.67 indicating that PureTech Health is being referred to more favorably in the news media.
Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.
Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.
46.5% of Scancell shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 5.0% of Scancell shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
PureTech Health has a consensus price target of GBX 455, suggesting a potential upside of 253.81%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Scancell.
Summary
PureTech Health beats Scancell on 11 of the 15 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
This page (LON:SCLP) was last updated on 7/6/2025 by MarketBeat.com Staff
